17 results on '"Yadava, Anjali"'
Search Results
2. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
- Author
-
Bennett, Jason W., Yadava, Anjali, Tosh, Donna, Sattabongkot, Jetsumon, Komisar, Jack, Ware, Lisa A., McCarthy, William F., Cowden, Jessica J., Regules, Jason, Spring, Michele D., Paolino, Kristopher, Hartzell, Joshua D., Cummings, James F., Richie, Thomas L., Lumsden, Joanne, Kamau, Edwin, Murphy, Jittawadee, Lee, Cynthia, Parekh, Falgunee, and Birkett, Ashley
- Subjects
- *
MALARIA vaccines , *PLASMODIUM vivax , *MALARIA treatment , *CIRCUMSPOROZOITE protein , *IMMUNE response , *PARASITEMIA - Abstract
Background: A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy- terminal regions of the circumsporozoite protein (CSP) and a truncated repeat region that contains repeat sequences from both the VK210 (type 1) and the VK247 (type 2) parasites, was developed as a vaccine candidate for global use. Methods: We conducted a first-in-human Phase 1 dose escalation vaccine study with controlled human malaria infection (CHMI) of VMP001 formulated in the GSK Adjuvant System AS01B. A total of 30 volunteers divided into 3 groups (10 per group) were given 3 intramuscular injections of 15μg, 30μg, or 60μg respectively of VMP001, all formulated in 500μL of AS01B at each immunization. All vaccinated volunteers participated in a P. vivax CHMI 14 days following the third immunization. Six non-vaccinated subjects served as infectivity controls. Results: The vaccine was shown to be well tolerated and immunogenic. All volunteers generated robust humoral and cellular immune responses to the vaccine antigen. Vaccination did not induce sterile protection; however, a small but significant delay in time to parasitemia was seen in 59% of vaccinated subjects compared to the control group. An association was identified between levels of anti-type 1 repeat antibodies and prepatent period. Significance: This trial was the first to assess the efficacy of a P. vivax CSP vaccine candidate by CHMI. The association of type 1 repeat-specific antibody responses with delay in the prepatency period suggests that augmenting the immune responses to this domain may improve strain-specific vaccine efficacy. The availability of a P. vivax CHMI model will accelerate the process of P. vivax vaccine development, allowing better selection of candidate vaccines for advancement to field trials. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Protective Efficacy of a Plasmodium vivax Circumsporozoite Protein-Based Vaccine in Aotus nancymaae Is Associated with Antibodies to the Repeat Region.
- Author
-
Yadava, Anjali, Hall, Cysha E., Sullivan, JoAnn S., Nace, Douglas, Williams, Tyrone, Collins, William E., Ockenhouse, Christian F., and Barnwell, John W.
- Subjects
- *
PLASMODIUM vivax , *CIRCUMSPOROZOITE protein , *RHESUS monkeys , *IMMUNOGLOBULINS , *VACCINE effectiveness - Abstract
We have previously reported that Vivax Malaria Protein 001 (VMP001), a vaccine candidate based on the circumsporozoite protein of Plasmodium vivax, is immunogenic in mice and rhesus monkeys in the presence of various adjuvants. In the present study, we evaluated the immunogenicity and efficacy of VMP001 formulated with a TLR9 agonist in a water-in-oil emulsion. Following immunization, the vaccine efficacy was assessed by challenging Aotus nancymaae monkeys with P. vivax sporozoites. Monkeys from both the low- and high-dose vaccine groups generated strong humoral immune responses to the vaccine (peak median titers of 291,622), and its subunits (peak median titers to the N-term, central repeat and C-term regions of 22,188; 66,120 and 179,947, respectively). 66.7% of vaccinated monkeys demonstrated sterile protection following challenge. Protection was associated with antibodies directed against the central repeat region. The protected monkeys had a median anti-repeat titer of 97,841 compared to 14,822 in the non-protected monkeys. This is the first report demonstrating P. vivax CSP vaccine-induced protection of Aotus monkeys challenged with P. vivax sporozoites. Author Summary: Plasmodium vivax is responsible for causing malaria in large parts of the globe, including regions with temperate climates not suited for the transmission of other Plasmodium species. In addition, P. vivax has the propensity to form dormant forms, known as hypnozoites, that can remain latent for weeks to months and reactive periodically to cause recurrent infections. Prevention of P. vivax malaria, more than any other form, will require a vaccine-based intervention due to limitations in treatment options. To this end, we tested the efficacy in non-human primates, of a vaccine based on circumsporozoite protein, a preerythrocytic stage antigen, of P. vivax. Aotus monkeys were immunized with clinical-grade antigen, combined with two immunomodulators, and then challenged with P. vivax sporozoites. Following challenge 66.7% of monkeys were protected. Analysis of serum samples indicated that protection was associated with antibodies to the central repeat region of the molecule, and that protection was lost upon waning of these antibodies. This is the first report demonstrating that active immunization with a recombinant protein can lead to complete protection in monkeys following sporozoite challenge, while also demonstrating a protective associate. Our data can help serve as a benchmark for down-selection of future vaccine formulations for P. vivax. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Protective Efficacy of a Plasmodium vivax Circumsporozoite Protein-Based Vaccine in Aotus nancymaae Is Associated with Antibodies to the Repeat Region.
- Author
-
Yadava, Anjali, Hall, Cysha E., Sullivan, JoAnn S., Nace, Douglas, Williams, Tyrone, Collins, William E., Ockenhouse, Christian F., and Barnwell, John W.
- Subjects
- *
AOTUS nancymaae , *PLASMODIUM vivax , *CIRCUMSPOROZOITE protein , *VACCINES , *IMMUNIZATION , *HUMORAL immunity , *MONKEYS - Abstract
We have previously reported that Vivax Malaria Protein 001 (VMP001), a vaccine candidate based on the circumsporozoite protein of Plasmodium vivax, is immunogenic in mice and rhesus monkeys in the presence of various adjuvants. In the present study, we evaluated the immunogenicity and efficacy of VMP001 formulated with a TLR9 agonist in a water-in-oil emulsion. Following immunization, the vaccine efficacy was assessed by challenging Aotus nancymaae monkeys with P. vivax sporozoites. Monkeys from both the low- and high-dose vaccine groups generated strong humoral immune responses to the vaccine (peak median titers of 291,622), and its subunits (peak median titers to the N-term, central repeat and C-term regions of 22,188; 66,120 and 179,947, respectively). 66.7% of vaccinated monkeys demonstrated sterile protection following challenge. Protection was associated with antibodies directed against the central repeat region. The protected monkeys had a median anti-repeat titer of 97,841 compared to 14,822 in the non-protected monkeys. This is the first report demonstrating P. vivax CSP vaccine-induced protection of Aotus monkeys challenged with P. vivax sporozoites. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Cross-Species Immunity Following Immunization With a Circumsporozoite Protein-Based Vaccine for Malaria.
- Author
-
Yadava, Anjali, Nurmukhambetova, Saule, Pichugin, Alexander V., and Lumsden, Joanne M.
- Subjects
- *
IMMUNIZATION , *MALARIA prevention , *VACCINATION , *CIRCUMSPOROZOITE protein , *PUBLIC health , *SERUM , *PLASMODIUM vivax - Abstract
Malaria continues to be a major public health concern, and there are concerted efforts to eliminate it. The quest for a vaccine remains a top priority, and vaccines based on the circumsporozoite protein (CSP) are among the lead candidates, with the RTS,S vaccine currently undergoing phase 3 testing in Africa. Previous studies have reported anti-CSP antibody-mediated enhancement of in vitro invasion of homologous sporozoites. This effect has been shown to be concentration dependent; high-level antibodies are inhibitory, whereas low-level antibodies lead to enhancement of invasion. Nondominant shared epitopes may lead to the generation of low titers of cross-reactive antibodies that may prove to be detrimental. We report cross-species recognition of Plasmodium falciparum and Plasmodium berghei sporozoites by anti-Plasmodium vivax CSP serum samples. In addition, we report that vaccination of mice with VMP001, a P. vivax CSP vaccine candidate, reduces, not enhances, P. berghei infection in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Safety and Tolerability of Mosquito Bite-Induced Controlled Human Infection with Plasmodium vivax in Malaria-Naive Study Participants-Clinical Profile and Utility of Molecular Diagnostic Methods.
- Author
-
Kamau, Edwin, Bennett, Jason W, and Yadava, Anjali
- Subjects
- *
PLASMODIUM vivax , *MOSQUITO control , *CLINICAL trial registries , *INFECTION control , *POLYMERASE chain reaction , *INFECTION , *MALARIA diagnosis , *PROTOZOA , *RESEARCH , *BITES & stings , *DNA , *MOLECULAR pathology , *MALARIA , *COMPARATIVE studies , *RESEARCH funding , *INSECTS - Abstract
Background: Plasmodium vivax controlled human malaria infection (PvCHMI) is an important tool for evaluation of drugs, vaccines, and pathologies associated with this parasite. However, there are few data on safety due to limited numbers of PvCHMIs performed.Methods: We report clinical and laboratory data, including hematological and biochemical profiles and adverse events (AEs), following mosquito bite-induced PvCHMI in malaria-naive study participants. Malaria diagnosis and treatment initiation was based on microscopic analysis of Giemsa-stained slides. Exploratory molecular assays were used to detect parasites using real-time polymerase chain reaction (PCR).Results: AEs were mild to moderate and no study-related severe AEs were observed in any study participants. The majority of symptoms were transient, resolving within 48 hours. Molecular diagnostic methods detected parasitemia in 100% of study participants before malaria diagnosis using microscopy. Of reported AEs, microscopy detected 67%-100%, quantitative PCR 79%-100%, and quantitative real-time reverse-transcription PCR 96%-100% of study participants prior to appearance of symptoms. Almost all symptoms appeared after initiation of treatment, likely as known consequence of drug treatment.Conclusions: PvCHMI is safe with the majority of infections being detected prior to appearance of clinical symptoms, which can be further alleviated by using sensitive molecular methods for clinical diagnosis. Clinical Trials Registration. NCT01157897. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Response to Odedra et al.
- Author
-
Kamau, Edwin, Bennett, Jason W, and Yadava, Anjali
- Subjects
- *
MALARIA , *AMINOTRANSFERASES - Published
- 2022
- Full Text
- View/download PDF
8. Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.
- Author
-
França, Camila Tenorio, White, Michael T., Wen-Qiang He, Hostetler, Jessica B., Brewster, Jessica, Frato, Gabriel, Malhotra, Indu, Gruszczyk, Jakub, Huon, Christele, Lin, Enmoore, Kiniboro, Benson, Yadava, Anjali, Siba, Peter, Galinski, Mary R., Healer, Julie, Chitnis, Chetan, Cowman, Alan F., Takashima, Eizo, Takafumi Tsuboi, and Wai-Hong Tham
- Subjects
- *
MALARIA , *VACCINES , *COHORT analysis , *IMMUNOGLOBULINS , *PLASMODIUM vivax , *RECOMBINANT proteins - Abstract
The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 P. vivax antigens, investigating their relationship with prospective risk of malaria in a cohort of 1-3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44-0.74, p<0.001-0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent P. vivax vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria.
- Author
-
Bennett, Jason W., Pybus, Brandon S., Yadava, Anjali, Tosh, Donna, Sousa, Jason C., McCarthy, William F., Deye, Gregory, Melendez, Victor, and Ockenhous, Christian F.
- Subjects
- *
PRIMAQUINE , *PLASMODIUM vivax , *CYTOCHROME P-450 CYP2D6 , *THERAPEUTICS - Abstract
A letter to the editor is presented in response to the article which discusses a study regarding the failure of primaquine as a drug for Plasmodium vivax malaria and the use of cytochrome P-450 isoenzyme 2D6 (CYP2D6) as an enzyme for primaquine.
- Published
- 2013
- Full Text
- View/download PDF
10. Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.
- Author
-
Longley, Rhea J., França, Camila T., White, Michael T., Kumpitak, Chalermpon, Sa-angchai, Patiwat, Gruszczyk, Jakub, Hostetler, Jessica B., Yadava, Anjali, King, Christopher L., Fairhurst, Rick M., Rayner, Julian C., Wai-Hong Tham, Wang Nguitragool, Sattabongkot, Jetsumon, and Mueller, Ivo
- Subjects
- *
PLASMODIUM vivax , *INFECTION , *IMMUNOGLOBULIN G , *HUMORAL immunity , *IMMUNE response - Abstract
Background: Thailand is aiming to eliminate malaria by the year 2024. Plasmodium vivax has now become the dominant species causing malaria within the country, and a high proportion of infections are asymptomatic. A better understanding of antibody dynamics to P. vivax antigens in a low-transmission setting, where acquired immune responses are poorly characterized, will be pivotal for developing new strategies for elimination, such as improved surveillance methods and vaccines. The objective of this study was to characterize total IgG antibody levels to 11 key P. vivax proteins in a village of western Thailand. Methods: Plasma samples from 546 volunteers enrolled in a cross-sectional survey conducted in 2012 in Kanchanaburi Province were utilized. Total IgG levels to 11 different proteins known or predicted to be involved in reticulocyte binding or invasion (ARP, GAMA, P41, P12, PVX_081550, and five members of the PvRBP family), as well as the leading pre-erythrocytic vaccine candidate (CSP) were measured using a multiplexed bead-based assay. Associations between IgG levels and infection status, age, and spatial location were explored. Results: Individuals from a low-transmission region of western Thailand reacted to all 11 P. vivax recombinant proteins. Significantly greater IgG levels were observed in the presence of a current P. vivax infection, despite all infected individuals being asymptomatic. IgG levels were also higher in adults (18 years and older) than in children. For most of the proteins, higher IgG levels were observed in individuals living closer to the Myanmar border and further away from local health services. Conclusions: Robust IgG responses were observed to most proteins and IgG levels correlated with surrogates of exposure, suggesting these antigens may serve as potential biomarkers of exposure, immunity, or both. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Particle-based platforms for malaria vaccines.
- Author
-
Wu, Yimin, Narum, David L., Fleury, Sylvain, Jennings, Gary, and Yadava, Anjali
- Subjects
- *
MALARIA vaccines , *IMMUNOGENETICS , *PEPTIDES , *IMMUNE response , *ANTIGENS - Abstract
Recombinant subunit vaccines in general are poor immunogens likely due to the small size of peptides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant subunit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants, are promising delivery vehicles for modifying the way in which immunogens are presented to both the innate and adaptive immune systems. These particle delivery platforms can also co-deliver non-specific immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particle-based delivery platforms in development of vaccines against malaria, a disease that claims over 600,000 lives per year, most of them are children under 5 years of age in sub-Sahara Africa. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
- Author
-
Vanloubbeeck, Yannick, Pichyangkul, Sathit, Bayat, Babak, Yongvanitchit, Kosol, Bennett, Jason W., Sattabongkot, Jetsumon, Schaecher, Kurt, Ockenhouse, Christian F., Cohen, Joe, and Yadava, Anjali
- Subjects
- *
IMMUNE response , *PLASMODIUM vivax , *CIRCUMSPOROZOITE protein , *PROTOZOAN vaccines , *RHESUS monkeys , *PARASITE antigens - Abstract
Highlights: [•] Immunogenicity of Plasmodium vivax circumsporozoite protein-based vaccine candidates was evaluated in rhesus macaques. [•] The study evaluated a soluble versus a particulate form of the vaccine antigen candidate. [•] The particulate form tended to afford enhanced humoral immunogenicity over the soluble antigen. [•] The particulate form induced antibodies to the AGDR epitope. [•] T-cell responses were induced by both formulations, with some quantitative and qualitative differences. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice
- Author
-
Lumsden, Joanne M., Nurmukhambetova, Saule, Klein, Jennifer H., Sattabongkot, Jetsumon, Bennett, Jason W., Bertholet, Sylvie, Fox, Christopher B., Reed, Steven G., Ockenhouse, Christian F., Howard, Randall F., Polhemus, Mark E., and Yadava, Anjali
- Subjects
- *
PLASMODIUM vivax , *MALARIA vaccines , *RECOMBINANT proteins , *IMMUNE response , *IMMUNOLOGICAL adjuvants , *LABORATORY mice , *CIRCUMSPOROZOITE protein , *IMMUNOFLUORESCENCE , *CELLULAR immunity , *DENDRITIC cells , *TOLL-like receptors - Abstract
Abstract: Plasmodium vivax is the major cause of malaria outside of sub-Saharan Africa and causes morbidity and results in significant economic impact in developing countries. In order to produce a P. vivax vaccine for global use, we have previously reported the development of VMP001, based on the circumsporozoite protein (CSP) of P. vivax. Our interest is to evaluate second-generation vaccine formulations to identify novel combinations of adjuvants capable of inducing strong, long-lasting immune responses. In this study, groups of C57BL/6J mice were immunized subcutaneously three times with VMP001 emulsified with synthetic TLR4 (GLA) or TLR7/8 (R848) agonist in stable emulsion (SE), a combination of the TLR4 and TLR7/8 agonists, or SE alone. Sera and splenocytes were tested for the presence of antigen-specific humoral and cellular responses, respectively. All groups of mice generated high titers of anti-P. vivax IgG antibodies as detected by ELISA and immunofluorescence assay. GLA-SE promoted a shift in the antibody response to a Th1 profile, as demonstrated by the change in IgG2c/IgG1 ratio. In addition, GLA-SE induced a strong cellular immune response characterized by multi-functional, antigen-specific CD4+ T cells secreting IL-2, TNF and IFN-γ. In contrast, mice immunized with SE or R848-SE produced low numbers of antigen-specific CD4+ T cells, and these T cells secreted IL-2 and TNF, but not IFN-γ. Finally, R848-SE did not enhance the immune response compared to GLA-SE alone. Based on these results, we conclude that the combination of VMP001 and GLA-SE is highly immunogenic in mice and may serve as a potential second-generation vaccine candidate against vivax malaria. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
14. Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine.
- Author
-
Moon, James J., Suh, Heikyung, Polhemus, Mark E., Ockenhouse, Christian F., Yadava, Anjali, and Irvine, Darrell J.
- Subjects
- *
ANTIGENS , *LIPIDS , *VACCINES , *BIOLOGICALS , *BILAYER lipid membranes , *PROTOZOAN vaccines , *IMMUNOGLOBULINS , *IMMUNOLOGICAL adjuvants - Abstract
The parasite Plasmodium vivax is the most frequent cause of malaria outside of sub-Saharan Africa, but efforts to develop viable vaccines against P. vivax so far have been inadequate. We recently developed pathogen-mimicking polymeric vaccine nanoparticles composed of the FDA-approved biodegradable polymer poly(lactide-co-glycolide) acid (PLGA) "enveloped" by a lipid membrane. In this study, we sought to determine whether this vaccine delivery platform could be applied to enhance the immune response against P. vivax sporozoites. A candidate malaria antigen, VMP001, was conjugated to the lipid membrane of the particles, and an immunostimulatory molecule, monophosphoryl lipid A (MPLA), was incorporated into the lipid membranes, creating pathogen-mimicking nanoparticle vaccines (VMP001-NPs). Vaccination with VMP001-NPs promoted germinal center formation and elicited durable antigen-specific antibodies with significantly higher titers and more balanced Th1/Th2 responses in vivo, compared with vaccines composed of soluble protein mixed with MPLA. Antibodies raised by NP vaccinations also exhibited enhanced avidity and affinity toward the domains within the circumsporozoite protein implicated in protection and were able to agglutinate live P. vivax sporozoites. These results demonstrate that these VMP001-NPs are promising vaccines candidates that may elicit protective immunity against P. vivax sporozoites. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction.
- Author
-
Moon, James J., Suh, Heikyung, Li, Adrienne V., Ockenhouse, Christian F., Yadava, Anjali, and Irvine, Darrell J.
- Subjects
- *
NANOPARTICLES , *IMMUNOLOGICAL adjuvants , *IMMUNOLOGIC memory , *TOLL-like receptors , *IMMUNE response , *T cells - Abstract
For subunit vaccines, adjuvants play a key role in shaping immunological memory. Nanoparticle (NP) delivery systems for antigens and/or molecular danger signals are promising adjuvants capable of promoting both cellular and humoral immune responses, but in most cases the mechanisms of action of these materials are poorly understood. Here, we studied the immune response elicited by NPs composed of multilamellar “stapled” lipid vesicles carrying a recombinant Plasmodium vivax circumsporozoite antigen, VMP001, both entrapped in the aqueous core and anchored to the lipid bilayer surfaces. Immunization with these particles and monophosphoryl lipid A (MPLA), a US Food and Drug Administration-approved immunostimulatory agonist for Toll-like receptor-4, promoted high-titer, high-avidity antibody responses against VMP001, lasting more than 1 y in mice at 10-fold lower doses than conventional adjuvants. Compared to soluble VMP001 mixed with MPLA, VMP001-NPs promoted broader humoral responses, targeting multiple epitopes of the protein and a more balanced Th1/Th2 cytokine profile from antigen-specific T cells. To begin to understand the underlying mechanisms, we examined components of the B-cell response and found that NPs promoted robust germinal center (GC) formation at low doses of antigen where no GC induction occurred with soluble protein immunization, and that GCs nucleated near depots of NPs accumulating in the draining lymph nodes over time. In parallel, NP vaccination enhanced the expansion of antigen-specific follicular helper T cells (Tfh), compared to vaccinations with soluble VMP001 or alum. Thus, NP vaccines may be a promising strategy to enhance the durability, breadth, and potency of humoral immunity by enhancing key elements of the B-cell response. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. Evidence for the Transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa.
- Author
-
Culleton, Richard, Ndounga, Mathieu, Zeyrek, Fadile Yildiz, Coban, Cevayir, Casimiro, Prisca Nadine, Takeo, Satoru, Tsuboi, Takafumi, Yadava, Anjali, Carter, Richard, and Tanabe, Kazuyuki
- Subjects
- *
PLASMODIUM vivax , *PLASMODIUM , *ERYTHROCYTES , *PERFORMANCE-enhancing drugs , *IMMUNOGLOBULINS , *ANTIGENS , *DRUG resistance in microorganisms , *ENZYME-linked immunosorbent assay , *INFECTIOUS disease transmission - Abstract
Plasmodium vivax is not thought to be transmitted in western and central Africa, because of the very high prevalence of the red blood cell Duffy-negative phenotype in local populations, a condition which is thought to confer complete resistance against blood infection with P. vivax. There are, however, persistent reports of travelers returning from this region with P. vivax infections. To investigate whether transmission occurs in this region, the presence of antibodies specific to P. vivax preerythrocytic-stage antigens was assessed in individuals from the Republic of the Congo. A total of 55 (13%) of 409 samples tested by enzyme-linked immunosorbent assay had antibodies to P. vivax-specific antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
17. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax
- Author
-
Bell, Brian A., Wood, James F., Bansal, Reeta, Ragab, Hatem, Cargo, John, Washington, Michael A., Wood, Chloe L., Ware, Lisa A., Ockenhouse, Christian F., and Yadava, Anjali
- Subjects
- *
VACCINE biotechnology , *MALARIA vaccines , *PLASMODIUM vivax , *ESCHERICHIA coli , *BACTERIAL vaccines , *PLASMODIUM falciparum , *BIOLOGICAL assay , *MONOCLONAL antibodies , *MALARIA prevention - Abstract
Abstract: The global eradication of malaria will require the development of vaccines to prevent infection cause by Plasmodium vivax in addition to Plasmodium falciparum. In an attempt to contribute to this effort we have previously reported the cloning and expression of a vaccine based on the circumsporozoite protein of P. vivax. The synthetic vaccine encodes for a full-length molecule encompassing the N-terminal and C-terminal regions flanking a chimeric repeat region representing VK210 and VK247, the two major alleles of P. vivax CSP. The vaccine, designated vivax malaria protein 001 (VMP001), was purified to >95% homogeneity using a three-column purification scheme and had low endotoxin levels and passed the rabbit pyrogenicity assay. The protein is recognized by monoclonal antibodies directed against the two repeat motifs, as well as polyclonal antibodies. Immunization with VMP001 induced high titer antibodies in mice using Montanide ISA 720. We currently have more than 10,000 doses of purified bulk and 1800 vials of formulated bulk vaccine available for clinical testing and VMP001 is currently undergoing further development as a candidate vaccine to prevent malaria in humans. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.